ABSTRACT
BACKGROUND
The randomised controlled trial (RCT) is widely accepted as the most powerful method to evaluate the effectiveness of new health technologies. However, low accrual and retention of participants can restrict the value of the trial, reducing the statistical power and generalisability [1, 2] . A recent review reported that 31% of trials funded by the UK Medical Research Council and National Health Service Research and Development Health Technology Assessment Programme that recruited participants between 1994 and 2002 did not achieve their original recruitment target [3] . Older people, in particular, are less likely to be included in RCTs, restricting generalisability further [4] .
Studies which have examined factors influencing trial recruitment have often focussed on cancer trials [1, 2, 5, 6] or hypothetical trials [7] . Trial recruitment is influenced by clinician and patient factors. Clinician barriers identified [1, 2, 5] include time pressures and constraints, lack of staff and training, concern about the impact on the clinician-patient relationship, concern for the patients, loss of professional autonomy, and lack of reward and recognition. Barriers to participant accrual and factors influencing participation in RCTs include the extra demands of the study (e.g. additional procedures and appointments), patient treatment preferences and treatment uncertainty [1, 2, 5] . Factors affecting older people's views on taking part in RCTs have seldom been examined.
The aim of this study was to explore the factors that influence older people to take part and remain in randomised trials through surveying participants who had completed a randomised controlled trial investigating the effect of multimineral and
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METHODS
The MAVIS trial design
The MAVIS trial was a randomised, double blinded placebo-controlled trial which investigated the effect of a multimineral and multivitamin supplement on infections, health service use and quality of life in 910 community-dwelling people aged 65yrs and older in the Grampian region of Scotland. Full details of the trial are provided elsewhere [8] . Grampian Research Ethics Committee gave approval for the study. All older people covered by the general practices involved were eligible to take part, unless their general practitioners (GPs) had indicated that they were too unwell to be contacted, or they already took vitamin or mineral supplements. Eligible older people were recruited by mailing them an initial invitation from their GP. Those who indicated they were interested returned a reply by post and were invited to an appointment in the GP's surgery.
Participants were asked to take one tablet a day for one year. They were also asked to record daily in a diary whether they had an infection and any contact with primary care for infection. At the end of each month participants returned the diary by post to the trial office, together with a questionnaire about trial tablet consumption over the last seven days. Ten percent of participants were also randomly selected to take part in a tablet count at six months and one year, requiring them to return unused tablets at these time points. Questionnaires for the Euroqol (EQ-5D) [9] and Short-Form-12 (SF-12) [10] were completed at the GP visit and sent out at six months and one year.
Participants also completed digit span forwards [11] and verbal fluency [12] cognitive function tests at recruitment, and then by phone at one year. Two researchers were involved in recruitment (a research nurse and a research dietitian).
Both researchers conducted the subsequent cognitive function tests by phone.
Participants were also phoned shortly after recruitment to check that there were no concerns about the study. The two researchers or trial secretary also phoned participants if diaries or questionnaires were not returned after one postal reminder, or if there were queries about information provided in the diaries. 
Follow-up questionnaire
The questions asked were informed by the findings from Prescott and colleague's systematic review [1, 2] and consultation with Professor Vikki Entwistle from the University of Dundee. Closed questions asked about motivating factors for taking part in a trial, health professional involvement, randomisation, use of a placebo, and filling in questionnaires. Quantitative methods were used to analyse participants' responses to closed questions in the questionnaire. Categorical data were analysed using Chi-squared tests. Two-sided statistical significance was at the 5% level. For dichotomous variables odds ratios (ORs) are presented with 95% confidence intervals (CIs) for the proportion of participants responding to the closed questions that were asked (active treatment vs blinded placebo). When comparing response rates for the proportions answering the closed questions between the treatment groups, non-responders were not included in the analysis. Participant data were stored, manipulated and analysed using SPSS version 11.5. Content analysis, a systematic method for assigning text to content categories [13] was used by PF to analyse the data given in response to open questions from the questionnaire.
Responses from all open questions were read and reread, and the categories were generated through close inspection and comparison of the data. A second researcher (SM) assisted with analysing a sample of responses for each question to enhance the reliability and reproducibility of the coding. The coded data set was then entered into an Access database. The themes of the analysis are illustrated using representative quotations.
RESULTS
Five hundred and forty (59%) of all 910 MAVIS trial participants returned the questionnaire. Participants responding to the questionnaire did not differ by gender, type of residence or smoking status from all those randomised to the trial. However, they averaged one year younger than those recruited to the trial (data not shown).
There was no statistically significant difference in proportions responding to the questionnaire between different arms of the trial [OR 1.12; 95% CI (0.83, 1.51); p = 0.450] see Table 1 .
Closed questions
There were no statistically significant differences in response rates to the closed questions between active and placebo arms of the trial, see Table 2 . Overall, 86% of those responding to the survey reported that helping the research team was very important to them when deciding to take part in a study like MAVIS. Seventy-two percent of people rated helping other people like themselves as being an important issue when deciding to take part in a study like MAVIS.
Under half of the people reported that being asked to take part by a doctor was very important to them. Whereas being asked by a nurse was rated to be less important when deciding to take part in a study. Thirty-four percent of respondents from the active treatment arm and 40% from the placebo arm reported that reducing their risk of illness was important to them when deciding to take part in a study.
Less important issues were knowing what was in the tablets, filling in a questionnaire or a diary. Least important issues were having to take tablets and having treatment decided by chance, particularly the possibility of having to take a placebo.
Open Questions
Written responses to the open questions are grouped into positive and negative aspects of the MAVIS trial, and factors impacting on people's considerations about taking part in future research.
Positive aspects of trial participation
Trial communication and organisation
Good communication and friendly personal contact between participants and trial staff seemed particularly important to people in the trial (n=88):
Participants indicated that they liked the way in which the trial was organised and conducted by trial staff. In particular MAVIS trial participants made specific ] reference to the value of face-to-face interviews, the design of the diaries, receiving Christmas cards and the general "friendliness" of those involved in the trial (n=52):
Participants also reported that they had liked the simplicity and "straightforward" nature of their involvement (n=76):
Negative aspects of trial participation
Infection Diaries and questionnaires
Although some people reported positive feelings towards completing their infection diary and completing questionnaires, this was the most frequently reported negative aspect of the trial (n=21). Some respondents suggested that instead of a daily diary they would have preferred a weekly diary: 
"Not really. But it would have been interesting to know what the real tablets consisted of, especially as I was informed that I had been on the real tablets and not the placebos." [Participant 092028.]
Duration of the trial
On the whole MAVIS participants were positive about the one year duration of the trial. However, a small number of participants stated a dislike about the duration and commitment required of them during their participation of the trial (n=6). It was suggested that a study for a six-month period would have been preferable and more convenient to them. In terms of feedback of the trial results, a small number of participants (n=6) indicating that they would like to have known the trial outcome sooner. However, the length of time taken to conduct the trial may have been greater that expected by the participants due to the staggered recruitment:
Taking part in future research
It became clear, that when participants were asked if they would consider taking part in future research, their responses reflected their experiences of being a participant in the MAVIS trial. Participants reported both reasons for and against taking part in future research. In total, over half of the 540 MAVIS respondents indicated that they would be willing to take part in future research (n=283). 
"The length of time the survey carried on for and the commitment necessary to see it through." [Participant 011090.] "Having wasted a year taking the placebo, I would have preferred if it had been 6 months vitamins and minerals and 6 months placebo, but still a blind test." [Participant 31015.] "Perhaps the length of your study. A six-month study might have been better. Most volunteers went on holiday during the year and you feel having to take tablets while you were away was an inconvenience. In my case I was in
Altruism
The most commonly described motivation by respondents for taking part in future research seemed to be based on a desire to "help" (n=181). Respondents described wanting to help other patients (n=92), and helping contribute towards furthering medical knowledge (n=76). The notion and desire to help by participating was a recurring theme throughout the data:
Giving something back
It was reported that participants' decisions to take part in the MAVIS trial and trials in general included the consideration of being able to "giving something back" to the health service by taking part in the trial (n=18): 
Weighing up future participation in trials
Some people's willingness to take part in future research appeared to depend on their expected involvement in the specific study, and any perceptions of personal benefit that might be gained through their participation:
Of the 540 respondents around a fifth reported their unwillingness to participate in future studies (n=117). Additionally some participants' considered how "worthwhile" a study would be when considering taking part in future research (n=15). The most frequently reported reason for not wishing to take part in future research was related to participants' perceptions of age and poor health status which were perceived as potential barriers towards taking part in any future study (n=32): 
Personal interest in study and results
Some participants reported their involvement in the trial as being "interesting" to them (n=17). Receiving feedback from the trial regarding the study's findings was an aspect of the trial that some people reported liking (n=16). A number of participants also reported that trial participation gave them a "routine" which fitted into their lifestyle (n=15): 
DISCUSSION
There are many barriers that prevent older people from taking part in randomised trials, restricting the value of trial findings.
Designing trials with older people
We found that the notion of "helping" is an important motivating factor in older people's decisions about participation in RCTs. Ways in which participants reported helping included helping other patients and helping by contributing to medical knowledge. Other studies have found similarly altruistic reasons for people to take part in research [1, 2, 5, 7, [14] [15] [16] . Although, it is not clear whether older people demonstrate more altruism than younger people.
Participants reported that their participation would "depend" on the demands of the trial, which will vary depending on the design of individual trials. Others have also identified that people's decisions to participate depend on additional demands such as taking trial medication or additional travel and appointments [5, 15] . It would be advisable to keep demands on participants to a minimum and make the trial as simple as possible, including providing transportation or covering its costs [17] .
Some participants of the MAVIS trial referred to keeping the daily infection diaries and pills as being "easy" and "straightforward". In particular, it is important to remember that this age group may already be taking several daily multiple dose medications in addition to any trial medication.
Regular communication and the friendly approach used by the trial team was an aspect of the trial that participants valued, as was good organisation and the way in which the trial was conducted. Given the age and state of health of some participants communication may be particularly important as they may live alone and have limited contact with other people. Similar social reasons for older people to take part in trials have also been found by Schron et al [18] .
A small number of MAVIS participants felt that they would have preferred to receive the results sooner. As recruitment was staggered it took longer for those recruited at the start of the trial to receive feedback on the results than those recruited at the end of the trial. It would be advisable to discuss the duration of the trial and the time taken to receive feedback of the results to people at recruitment. Some participants had concerns regarding the placebo, which have been reported in other studies [1, 2, 5, 15, 19, 20] . It is particularly important to have adequate time to clearly explain the reasons for randomisation and a placebo, concepts which are difficult for participants of all ages to grasp and recall [5] [6] [7] 16, 21] .
Planning trials with older people involves considerations specifically for this age group, and potential participants should be involved in the study design process [7] .
Some people felt that their health and age would not allow them to take part in a trial or that they might not be of use to the trial as they were too old. Ill health and depression in this age group are particularly important reasons for discontinuing a trial once enrolled [22] . Explaining the need for older people, despite poor health, to participate in trials may help the generalisability of clinical trials. Trial staff need to be sensitive to these issues, as well as avoiding prejudicial terms such as 'geriatric', which may discourage older people from participating [23] .
Limitations
The results of this study must be interpreted within the context of the MAVIS trialparticipants completed the questions having already taken part in the trial and had received the trial results. We did not seek responses from people refusing to participate in the trial which would have given a broader perspective.
The questionnaire was not piloted with older people prior to administration, as it was not feasible due to the very short timescale of the funding. However, the questions asked were provided by researchers who had already undertaken research on patient participation in trials. Piloting the questionnaire may have identified potential issues which could have been addressed [24] .
The questions were asked in the order of closed questions first, followed by open questions. The closed questions may have prompted participants' responses to the open questions that followed. However, using both closed and open questions in that order is useful for topics about which little is known [25] . [21, 23, 26] . Thus participants' responses may be less relevant to participants recruited to trials related to life-threatening illnesses. Most MAVIS trial participants were under 85yrs of age, so findings may not be generalisable to the oldest old.
Conclusions
Older people have often been excluded from clinical trials as a direct consequence of exclusion criteria focussing on pre-existing illnesses and medication use, rather than age per se [6] . With the need to ensure that older people are represented in clinical trials, we need to ensure that concerns of older people are properly addressed. * OR 1.12; 95% CI (0.83, 1.51); p = 0.450 
